BioLineRx Secures Patent for GLIX1, Expanding Cancer Treatment Potential Beyond Glioblastoma

BioLineRx Secures Key Patent for Cancer Treatment Candidate GLIX1

BioLineRx Ltd. announces a significant milestone with the issuance of a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) for a crucial patent concerning its cancer treatment candidate, GLIX1. Titled "Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies," this patent addresses the use of GLIX1 in treating various cancers, specifically those where cytidine deaminase (CDA) is not over-expressed. This condition is prevalent in over 90% of all cancer types, providing BioLineRx with the opportunity to broaden GLIX1’s use beyond its initial focus on glioblastoma. The patent not only strengthens the intellectual property around GLIX1 but also extends its protection until 2040, with a possible additional five-year extension, solidifying the company’s strategy to explore wider applications.

The potential of GLIX1 lies in its unique mechanism of action that targets the DNA damage response in cancer cells. This innovative approach positions GLIX1 as a promising candidate for patients facing challenging cancer diagnoses, particularly where traditional therapies have limited effectiveness. CEO Philip Serlin emphasizes that the patent serves to fortify BioLineRx’s commitment to investigating GLIX1’s capabilities across a broader spectrum of cancers, enhancing its potential to change treatment paradigms. The company's first-in-human study for GLIX1 in glioblastoma is scheduled to begin in early 2026, while pre-clinical studies are ongoing in various cancer models, indicating a robust pipeline for GLIX1’s development.

In addition to the newly granted patent, GLIX1 benefits from a comprehensive global patent portfolio, which includes its application as a monotherapy and in conjunction with existing anti-cancer agents. This versatility is particularly significant in treating central nervous system cancers and in combination with PARP inhibitors, which are effective for homologous recombination-proficient tumors. The strategic positioning of GLIX1 within the oncology landscape highlights BioLineRx’s dedication to developing innovative therapies for patients with rare and hard-to-treat cancers.

As BioLineRx advances its clinical and pre-clinical studies for GLIX1, the company remains at the forefront of oncology research, striving to provide new hope for patients facing the challenges of cancer treatment. The issuance of this patent not only marks a critical achievement for BioLineRx but also underscores the importance of intellectual property in biopharmaceutical innovation, particularly within the competitive oncology sector.